Interna

[Comment] Astegolimab and the new era of biologics in COPD care

Chronic obstructive pulmonary disease (COPD) affects 480 million people worldwide and this is projected to increase to nearly 600 million over the next two decades.1 Long-acting beta agonists (LABA) and long-acting muscarinic antagonists (LAMA), often combined with inhaled corticosteroids (ICS), are the cornerstone of

ME

MedScopeGlobal Editorial

May 26, 2026

MedScopeGlobal

Shrnutí

Chronic obstructive pulmonary disease (COPD) affects 480 million people worldwide and this is projected to increase to nearly 600 million over the next two decades.1 Long-acting beta agonists (LABA) and long-acting muscarinic antagonists (LAMA), often combined with inhaled corticosteroids (ICS), are the cornerstone of

Klinický význam

Tento článek byl automaticky zpracován ze zdroje The Lancet. Pro plné redakční zpracování nastavte OPENAI_API_KEY.

Zdroj

Původní publikace

MedScopeGlobal — ověřte vůči primární literatuře před klinickým použitím.

Related coverage